The Government of the Russian Federation has granted permission to PSK Pharma to produce the drug Insudive®, an analog of Ozempik®, which left Russia. It is expected that the new drug will help meet the demand of the domestic healthcare system for injectable semaglutide.
The drug Ozempik, which is in high demand in the treatment of type 2 diabetes worldwide, has been on the defective list in Russia for a long time. At the beginning of 2023, Novo Nordisk announced the termination of its supplies to the country. Despite this, the Danish company's drug is still under patent protection, which limits the ability of domestic manufacturers to produce vital medicines.
In July of this year, PSK Pharma registered an analogue of Ozempik®, Incudive®. Obtaining compulsory licensing from the Government of the Russian Federation gives the company the opportunity to produce its own drug until December 31, 2025 without the consent of the patent owner. This decision is due to the extreme necessity related to the protection of the life and health of the country's citizens.
"Our task as a responsible manufacturer is to provide patients with type 2 diabetes with access to modern and high–quality therapy. The company has everything it needs for this – expertise, staff, and production facilities. Realizing the high social importance of the drug, the Russian Government has granted our company permission to produce injectable semaglutide. This allows us to produce Incudive® in the interests of the country's residents within the framework of the law" - Evgenia Shapiro, CEO of PSK Pharma.